Evidence map›Paper›PMID 20710027›Full record

ArticleThe Journal of biological chemistry2010

Novel changes in NF-{kappa}B activity during progression and regression phases of hyperplasia: role of MEK, ERK, and p38.

Parthasarathy Chandrakesan, Ishfaq Ahmed, Tariq Anwar, Yu Wang, Shubhashish Sarkar, Pomila Singh, Sara Peleg, Shahid Umar

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Galectin-8, cytokines, and the storm.Biochemical Society transactions · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Microbiome and Colorectal Cancer.Current colorectal cancer reports · 2018
    Article
  10. The germ-organ theory of non-communicable diseases.Nature reviews. Microbiology · 2018
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parthasarathy ChandrakesanFrom the Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Ishfaq AhmedFrom the Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Tariq AnwarCentre for Molecular Biosciences, University of Ulster, BT52 1SA Coleraine, United Kingdom.
Yu WangDepartments of Internal Medicine, Galveston, Texas 77555.
Shubhashish SarkarNeuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555.
Pomila SinghNeuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555.
Sara PelegDepartment of Endocrine Neoplasia and Hormone Disorder Research, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030.
Shahid UmarFrom the Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104. Electronic address: Shahid-Umar@ouhsc.edu.

Funding

Role of Annexin-II in growth factor/co-carcinogenic effects of progastrinR01CA097959 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SINGH, POMILA · 2003 to 2015
$3.7M
Growth Factors, Curcumin and Colon CarcinogenesisR01CA114264 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SINGH, POMILA · 2006 to 2010
$1.3M
Beta-Catenin/NF-kB in Hyperplasia/Neoplasia of Colonic Crypts: ChemopreventionR01CA131413 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI UMAR, SHAHID · 2008 to 2011
$1.2M
Diet and the Calcium Channel TRPV6 in Colon HyperplasiaR21CA131936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PELEG, SARA · 2009 to 2010
$373k
NCI NIH HHS CA114264NCI NIH HHS R01 CA097959NCI NIH HHS R01 CA114264NCI NIH HHS R01 CA131413NCI NIH HHS R01 CA 97959NCI NIH HHS R21 CA131936
6 · The paper itself

Abstract

Utilizing the Citrobacter rodentium-induced transmissible murine colonic hyperplasia (TMCH) model, we measured hyperplasia and NF-κB activation during progression (days 6 and 12 post-infection) and regression (days 20-34 post-infection) phases of TMCH. NF-κB activity increased at progression in conjunction with bacterial attachment and translocation to the colonic crypts and decreased 40% by day 20. NF-κB activity at days 27 and 34, however, remained 2-3-fold higher than uninfected control. Expression of the downstream target gene CXCL-1/KC in the crypts correlated with NF-κB activation kinetics. Phosphorylation of cellular IκBα kinase (IKK)α/β (Ser(176/180)) was elevated during progression and regression of TMCH. Phosphorylation (Ser(32/36)) and degradation of IκBα, however, contributed to NF-κB activation only from days 6 to 20 but not at later time points. Phosphorylation of MEK1/2 (Ser(217/221)), ERK1/2 (Thr(202)/Tyr(204)), and p38 (Thr(180)/Tyr(182)) paralleled IKKα/β kinetics at days 6 and 12 without declining with regressing hyperplasia. siRNAs to MEK, ERK, and p38 significantly blocked NF-κB activity in vitro, whereas MEK1/2-inhibitor (PD98059) also blocked increases in MEK1/2, ERK1/2, and IKKα/β thereby inhibiting NF-κB activity in vivo. Cellular and nuclear levels of Ser(536)-phosphorylated (p65(536)) and Lys(310)-acetylated p65 subunit accompanied functional NF-κB activation during TMCH. RSK-1 phosphorylation at Thr(359)/Ser(363) in cellular/nuclear extracts and co-immunoprecipitation with cellular p65-NF-κB overlapped with p65(536) kinetics. Dietary pectin (6%) blocked NF-κB activity by blocking increases in p65 abundance and nuclear translocation thereby down-regulating CXCL-1/KC expression in the crypts. Thus, NF-κB activation persisted despite the lack of bacterial attachment to colonic mucosa beyond peak hyperplasia. The MEK/ERK/p38 pathway therefore seems to modulate sustained activation of NF-κB in colonic crypts in response to C. rodentium infection.

Indexed as

Citrobacter rodentiumAnimalsChemokine CXCL1ColonColonic DiseasesEnterobacteriaceae InfectionsFlavonoidsGene Expression RegulationHyperplasiaI-kappa B KinaseI-kappa B ProteinsMAP Kinase Kinase 1MAP Kinase Kinase 2MAP Kinase Signaling SystemMiceMitogen-Activated Protein Kinase 32-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneChemokine CXCL1CHUK protein, humanCxcl1 protein, mouseFlavonoidsI-kappa B KinaseI-kappa B ProteinsMap2k1 protein, mouseMap2k2 protein, mouseMAP Kinase Kinase 1MAP Kinase Kinase 2Mitogen-Activated Protein Kinase 3NF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mousep38 Mitogen-Activated Protein KinasesRela protein, mouseRibosomal Protein S6 Kinases, 90-kDaRps6ka1 protein, mouseTranscription Factor RelA

Identifiers

PMID20710027
PMCPMC2963366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.